Back to search results

Magnesium and Prochlorperazine for Migraine Treatment

This study is looking at whether adding magnesium to prochlorperazine (a medicine often used for nausea and migraines) can better reduce migraine pain. You might be able to join if you are 18 or older, can speak English, and have been diagnosed with migraines. The study aims to see how much your pain changes from the start of treatment to 30 minutes after the infusion begins. The current status of this study is unclear, but it plans to enroll 100 people.

Study design
This is a randomized, double-blinded study, meaning participants are randomly assigned to a treatment group and neither you nor your doctors will know which treatment you are receiving. It will compare magnesium plus prochlorperazine to a placebo (inactive substance) plus prochlorperazine.
What's involved
Participants will receive prochlorperazine followed by either magnesium or a placebo (normal saline) as an intravenous (IV) infusion.
Compensation
Not stated in the trial record.
Follow-up
The main measurement of pain change is taken from the start of the infusion to 30 minutes after it begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06904287

Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines

Recruiting
PHASE3Ages 18+InterventionalTreatment
Wake Forest University Health Sciences
~100 participants
Updated 2026-01-22 on ClinicalTrials.gov
What's tested:MagnesiumPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean change in pain - baseline to 30 minutes
Measured over Baseline to 30 minutes after initiation of infusion

Conditions

Migraine

Explore related trials

Migraine

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Ryan McKillip, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

Ryan McKillip, MD
[email protected]
708-684-6230
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years or older
Able to provide informed consent
English speaking
Primary diagnosis of migraine. Patient with a previous diagnosis of migraine, who experience headaches with typical migraine features (e.g at least 2-3 of the following: recurrent, unilateral, pounding or throbbing in nature, associated with nausea), AND with a clinical exclusion of migraine mimics

Exclusion

Pregnancy defined as a positive urine HCG
Allergy or sensitivity to study drug
Stated history of renal insufficiency
Documented history of myasthenia gravis
Consumption of study drug within 48 hours prior to enrollment
Previously enrolled in this trial during a different patient encounter

What this trial measures

  • Mean change in pain - baseline to 30 minutesBaseline to 30 minutes after initiation of infusion

    Change in pain score 30 minutes after initiation of infusion. Pain score is measured on a 0-11 point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain.